VolitionRx Q1 revenue $170k (+15% YoY); cash $11.8M; targets $10M annual cost cuts for 2025 cash flow neutrality

VOLITIONRX LTD

2025-Q1 EPS reported -$0.10 revenue$171,535

Q1 2024 revenue ~$170,000, up 15% YoY; cash and equivalents $11.8M as of March 31, 2024.
Targeting $10M in annualized cost reductions; aiming for cash flow neutrality in 2025 via non-dilutive funding, revenue growth, and milestone payments.
Applied for $25M in U.S. and $18M in European non-dilutive grants.
Expects substantial Nu.Q NETs and Capture-PCR clinical data by end of June; then laser focus on commercialization.
Volition Vet revenue expected to accelerate in H2 2024 after recent Antech and Fujifilm product launches.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

VOLITIONRX LTD reported the first quarter of 2024 results: revenue approximately $170,000 in revenue.

Period: the first quarter of 2024
Revenue: approximately $170,000 in revenue
Result: reported results

Exact text from the filing

recorded approximately $170,000 in revenue in the first quarter of 2024, up 15% over the prior year

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

VOLITIONRX LTD filing history →

Source: SEC EDGAR

accession 0001477932-24-002772

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.